| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Lenvatinib |
| Brand | Kisplyx® |
| Indication | In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy. |
| Assessment Process | |
| Rapid review commissioned | 05/05/2017 |
| Rapid review completed | 18/05/2017 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.
